BioSpace News Archive

MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), announced today the publication of data in the Journal of Gerontology: Biological Sciences (JGBS) from a pre-clinical study of MYMD-1® demonstrating four-fold greater improvements than rapamycin in delaying aging and extending the life of mice who began treatment at the human equivalent of 60 years of age.

Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced topline results that neither the primary endpoint of Overall Response Rate (ORR) nor the key secondary endpoint in Progression Free Survival (PFS) achieved statistical significance in the multi-center, international Phase III AGENT Study of arfolitixorin in combination with 5-FU, oxaliplatin and bevacizumab in metastatic colorectal cancer (mCRC).

Genixus, a pharmaceutical company focused on transforming acute and critical care medicines, today announced that it has received both federal registration and state licensing to begin commercial production of its new KinetiX™ RTA Platform brand of pre-filled syringes.

Kaia Health, the largest global digital therapeutics company on a mission to make high-quality, evidence-based therapies accessible to anyone, anytime, today announced results from the Rise-uP randomized controlled trial, which demonstrated that the use of digital multimodal therapy leads to a significant reduction in back pain.

ImmunAbs Inc. (www.immunabs.com) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States.

LG Chem recently announced that the Company has submitted an IND application to the US FDA for its first independent global Phase 3 clinical trial of its new gout drug ‘Tigulixostat’ (clinical program name: EURELIA_1 Study).

CardiolRx is a pharmaceutically produced oral cannabidiol formulation being developed for the treatment of acute and chronic inflammation associated with heart disease.

The Europe diabetic foot ulcer treatment market size was estimated at around USD 1.52 billion in 2021 and it is projected to hit around USD 2.4 billion by 2030, growing at a CAGR of 5.21% from 2022 to 2030.

According to Vision Research Report, the Europe hyperspectral imaging market was valued at USD 2.94 billion in 2021 and it is predicted to surpass around USD 7.52 billion by 2030 with a CAGR of 11.0% from 2022 to 2030.

According to Latest Study, the Europe sinus tissue resection market size was estimated at around USD 153.06 million in 2021 and it is projected to hit around USD 263.81 million by 2030, growing at a CAGR of 6.24% from 2022 to 2030.